Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A 20-year-old with thinning hair has low vitamin D and normal testosterone. They are prescribed oral minoxidil and vitamin D, and are questioning if finasteride is also necessary.

The user had a hair transplant with 2000 grafts in the frontal and mid-scalp areas and has been using finasteride and minoxidil for 3 months. The crown area is expected to improve with continued treatment, and results are generally positive so far.

HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.

Scalp Botox may help hair loss by relaxing muscles and increasing blood flow, potentially benefiting conditions other than androgenetic alopecia. DHT affects hair follicles differently, causing tension and hair loss in some areas but not others.

A user is curious why their DHT levels are not higher despite using 400mg of testosterone without finasteride, and wonders if zinc or GHK-Cu injections could be influencing this. Another user suggests that more testosterone typically leads to more DHT, but the user might be fortunate not to exceed normal DHT levels.

The conversation discusses the potential of cinnamic acid for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Taking potassium chloride and magnesium stopped minoxidil-induced palpitations. The user is considering continuing minoxidil with these supplements.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

The conversation discusses verteporfin as a potential treatment for hair regeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Green tea extract and soy isoflavones may help with hair loss by inhibiting DHT and providing additional health benefits. Combining these with finasteride and possibly using nizoral shampoo could enhance effectiveness in managing hair loss.

Whether using both Fluridil and Alfatradiol together could be more effective than either one alone as a hair loss treatment, given their different mechanisms of action.

Genetic differences in hair follicles affect hair loss patterns. Treatments discussed include finasteride, dutasteride, minoxidil, and RU58841.

A 31-year-old male with low normal-range testosterone and DHT is experiencing significant hair loss from the front scalp. He has tried Minoxidil, vitamin D3 and B12 supplements, and exercises regularly but is still seeking the root cause and effective treatment.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Shampoos can help with thinning hair by improving scalp health and reducing breakage, but they can't address genetic or hormonal causes. Effective treatments often include using topical minoxidil and finasteride, while the right shampoo varies per individual needs.

Saw palmetto and pumpkin seed oil are generally considered ineffective for hair regrowth compared to finasteride and minoxidil. Users report that finasteride, minoxidil, and sometimes dutasteride are more reliable for maintaining and regrowing hair.

The user started balding at 16/17 and tried various treatments including minoxidil, finasteride, and dutasteride with little success. They recently started applying diclofenac gel to their bald areas and noticed some hair regrowth, attributing this to diclofenac's ability to lower prolactin levels and its anti-inflammatory effects.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

Current hair loss treatments include finasteride, dutasteride, minoxidil, and derma rolling. New treatments like TDM-105795, GT20029, and others show promise but require more testing and time before approval.

The conversation discusses taurine supplements for hair growth, highlighting their potential to reduce DHT and improve hair health. A user comments that people often try alternatives to finasteride.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.